Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 2
2005 1
2006 2
2007 1
2011 1
2012 2
2015 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Tolcher AW, LoRusso P, Arzt J, Busman TA, Lian G, Rudersdorf NS, Vanderwal CA, Kirschbrown W, Holen KD, Rosen LS. Tolcher AW, et al. Among authors: busman ta. Cancer Chemother Pharmacol. 2015 Nov;76(5):1025-32. doi: 10.1007/s00280-015-2883-8. Epub 2015 Sep 29. Cancer Chemother Pharmacol. 2015. PMID: 26420235 Clinical Trial.
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Tolcher AW, LoRusso P, Arzt J, Busman TA, Lian G, Rudersdorf NS, Vanderwal CA, Waring JF, Yang J, Holen KD, Rosen LS. Tolcher AW, et al. Among authors: busman ta. Cancer Chemother Pharmacol. 2015 Nov;76(5):1041-9. doi: 10.1007/s00280-015-2882-9. Epub 2015 Oct 1. Cancer Chemother Pharmacol. 2015. PMID: 26429709 Clinical Trial.
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L. Rudin CM, et al. Among authors: busman ta. Clin Cancer Res. 2012 Jun 1;18(11):3163-9. doi: 10.1158/1078-0432.CCR-11-3090. Epub 2012 Apr 11. Clin Cancer Res. 2012. PMID: 22496272 Free PMC article. Clinical Trial.
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Roberts AW, et al. Among authors: busman ta. J Clin Oncol. 2012 Feb 10;30(5):488-96. doi: 10.1200/JCO.2011.34.7898. Epub 2011 Dec 19. J Clin Oncol. 2012. PMID: 22184378 Free PMC article. Clinical Trial.
12 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page